| Project/Area Number |
08457320
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Nagoya University |
|---|
Principal Investigator |
NAKAO Akimasa Nagoya University, Medicine, Associate Professor, 医学部, 助教授 (70167542)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MIYOSHI Koji Nagoya University, Medicine, Research fellow, 医学部, 医員
KANEKO Tetsuya Nagoya University, Medicine, Research fellow, 医学部, 医員
NONAMI Toshiaki Nagoya University, Medicine, Assistant Professor, 医学部, 講師 (80189422)
|
|---|
| Project Period (FY) |
1996 – 1997
|
| Project Status |
Completed (Fiscal Year 1997)
|
| Budget Amount *help |
¥1,700,000 (Direct Cost: ¥1,700,000)
Fiscal Year 1997: ¥1,700,000 (Direct Cost: ¥1,700,000)
|
|---|
| Keywords | pancreatic cancer / AAV vector / gene therapy / infectability / AAVベクター |
|---|
| Research Abstract |
The use of adeno-associated virus (AAV) vectors to transfer genes recently has been described as highly promising. [Aim] We examined the precise efficacy of recombinant AAV (rAAV) to infect pancreatic cancer cells. [Results] We have examined the infectability of rAAV containing the NeoR gene into five human pancreatic cancer cell lines such as SW1990, MIAPaCa2, Panc1, Capan2 and Capan1. The infectability of rAAV/NeoR to the pancreatic cell lines showed the following results. SW1990(1.0*10^4 CFU/ml), MIAPaCa2 (5.5*10^3 CFU/ml), Panc1 (3.0*10^3 CFU/ml), CAPAN2(1.5*10^3 CFU/ml), CAPAN1 (3.3*10^3 CFU/ml). The overall infectability was 0.8-25% in comparison with Hela cells. However, we could not detect the band of NeoR gene in the cells which could grow under medium with G418. Although it was reported that AAV vector could be integrated in some cells, our question is addressed when and how the NeoR gene in the infected pancreatic cells was disappeared.
On the other hand, the transduction of LacZ using the simultaneous infection with AAV vector (containing LacZ gene) and mutant HSV(ICPDELTA6) (so-called combination therapy) was about 70 times higher than one with only AAV vector in SW1990. At the present, our experiments about combination therapy are ongoing.
|
